China's National Medical Products Administration accepted the drug marketing authorization application of Jiangsu Hengrui Pharmaceuticals' (SHA:600276, HKG:1276) unit, Beijing Shengdi Pharmaceutical, for SHR-2004 injection, according to a Tuesday disclosure in a Shanghai bourse filing.
The drug is used to prevent venous thromboembolism in adult patients undergoing elective knee replacement surgery.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments